Brad P Dieter1, Sterling M McPherson2, Maryam Afkarian3, Ian H de Boer4, Rajnish Mehrotra5, Robert Short6, Celestina Barbosa-Leiker6, Radica Z Alicic7, Rick L Meek8, Katherine R Tuttle9. 1. Providence Medical Research Center, Providence Health Care. Electronic address: Brad.dieter@providence.org. 2. Providence Medical Research Center, Providence Health Care; Washington State University. 3. University of Washington; Nephrology Division, Kidney Research Institute. 4. Washington State University Elson S. Floyd College of Medicine; University of Washington; Nephrology Division, Kidney Research Institute. 5. University of Washington. 6. Washington State University Elson S. Floyd College of Medicine. 7. Providence Medical Research Center, Providence Health Care; University of Washington. 8. Providence Medical Research Center, Providence Health Care. 9. Providence Medical Research Center, Providence Health Care; University of Washington; Nephrology Division, Kidney Research Institute.
Abstract
AIMS: To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. METHODS: In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. RESULTS: Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean±SD age of 57±7.5years. At baseline, participants had hemoglobin A1c of 8.6±2.3%, systolic blood pressure of 153±27mm Hg, body mass index of 31±9kg/m2, median urine-albumin-to-creatinine ratio of 1861mg/g (interquartile range 720-3912mg/g), and estimated glomerular filtration rate of 55.7±22.3ml/min/1.73m2. Over a median duration of follow-up of 3.5years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43-6.40, p=0.003) in the highest (>1.0 μg/ml) compared to the lowest (<0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c=0.017). CONCLUSIONS: In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.
AIMS: To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. METHODS: In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. RESULTS:Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean±SD age of 57±7.5years. At baseline, participants had hemoglobin A1c of 8.6±2.3%, systolic blood pressure of 153±27mm Hg, body mass index of 31±9kg/m2, median urine-albumin-to-creatinine ratio of 1861mg/g (interquartile range 720-3912mg/g), and estimated glomerular filtration rate of 55.7±22.3ml/min/1.73m2. Over a median duration of follow-up of 3.5years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43-6.40, p=0.003) in the highest (>1.0 μg/ml) compared to the lowest (<0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c=0.017). CONCLUSIONS: In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.
Authors: T Shoji; M Emoto; T Kawagishi; E Kimoto; A Yamada; T Tabata; E Ishimura; M Inaba; Y Okuno; Y Nishizawa Journal: Atherosclerosis Date: 2001-06 Impact factor: 5.162
Authors: William C Knowler; Josef Coresh; Robert C Elston; Barry I Freedman; Sudha K Iyengar; Paul L Kimmel; Jane M Olson; Rosemarie Plaetke; John R Sedor; Michael F Seldin Journal: J Diabetes Complications Date: 2005 Jan-Feb Impact factor: 2.852
Authors: Rick L Meek; Renee C LeBoeuf; Sandeep A Saha; Charles E Alpers; Kelly L Hudkins; Sheryl K Cooney; Robert J Anderberg; Katherine R Tuttle Journal: Nephrol Dial Transplant Date: 2013-01-12 Impact factor: 5.992
Authors: Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey Journal: JAMA Date: 2012-05-09 Impact factor: 56.272
Authors: Pierre-Jean Saulnier; Brad P Dieter; Stephanie K Tanamas; Sterling M McPherson; Kevin M Wheelock; William C Knowler; Helen C Looker; Rick L Meek; Robert G Nelson; Katherine R Tuttle Journal: Am J Nephrol Date: 2017-09-22 Impact factor: 3.754
Authors: Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle Journal: Endocr Rev Date: 2020-10-01 Impact factor: 19.871
Authors: Brad P Dieter; Rick L Meek; Robert J Anderberg; Sheryl K Cooney; Jen L Bergin; Hongyu Zhang; Viji Nair; Matthias Kretzler; Frank C Brosius; Katherine R Tuttle Journal: PLoS One Date: 2019-02-14 Impact factor: 3.240